Dateline – November 17 2025 | Lund, Sweden BioInvent International AB (“BioInvent”), a clinical-stage biotech company focused on novel immuno-modulatory antibodies, announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation (ODD) for its investigational therapeutic antibody BI‑1808, targeting Cutaneous T‑cell Lymphoma (CTCL). The European Commission is now expected to grant the formal designation within 30 days.
Science Significance
BI-1808 is a first-in-class anti-TNFR2 monoclonal antibody designed to target tumor-associated regulatory T cells (Tregs) via the TNFR2 receptor, which is over-expressed in certain cancer micro-environments. BioInvent In an ongoing Phase 2a trial in CTCL, nine evaluable patients achieved a 100 % disease control rate (1 complete response, 4 partial responses, 4 stable disease) with primarily Grade 1-2 adverse events. BioInvent The science is significant: targeting the immune suppressive Treg population via TNFR2 opens a novel immune-modulatory axis in hematologic oncology, addressing a major unmet need in a rare, aggressive T-cell lymphoma.
Regulatory Significance
Advertisement
The positive COMP opinion for Orphan Drug Designation signals strong regulatory support for BI-1808 in the European Union. Orphan designation offers incentives including protocol assistance, reduced regulatory fees, and up to ten years of market exclusivity once approved. BioInvent This designation enhances BioInvent’s regulatory positioning for expedited development, facilitates regulatory guidance and may attract accelerated assessment routes, thereby de-risking and shortening the pathway to market.
Business Significance
From a strategic business perspective, this milestone strengthens BioInvent’s pipeline value and partnering attractiveness. The orphan designation adds potentially exclusive market rights in the EU and enhances commercial prospects in rare oncology. The positive data and regulatory backing increase licensing leverage, attract investor confidence, and may accelerate deal-making opportunities for the company’s immuno-oncology assets. BioInvent’s ability to convert this into tangible value will depend on successful clinical progression, scalable manufacturing, and eventual market access.
Patients’ Significance
For patients facing CTCL—a rare, debilitating form of T-cell lymphoma manifesting in skin lesions, itching, and systemic involvement—this development offers renewed hope. Existing treatments are limited, and disease progression often severely impacts quality of life. The positive scientific and regulatory signals around BI-1808 raise the potential for a more effective and tolerable therapy, addressing unmet need and improving outcomes for patients with relapsed or refractory disease.
Policy Significance
Orphan drug designations in the EU reflect broader health-policy goals of incentivising innovation for rare diseases, aligning industry effort with public health priorities. This milestone underscores the importance of regulatory frameworks that encourage investment into low-prevalence conditions. For national health systems and payers, upcoming therapies such as BI-1808 will test reimbursement and access models for rare tumour treatments within oncology and hematology.
In summary, the EMA’s positive opinion on Orphan Drug Designation for BI-1808 marks a meaningful advance in the development of novel immunotherapies for CTCL. With strong early clinical results, a robust scientific rationale, and regulatory momentum, BioInvent is advancing an asset that may transform outcomes in a difficult-to-treat rare lymphoma. For patients, clinicians, regulators and investors alike, this is a rare disease story worth watching as it unfolds.
Source: BioInvent International AB press release
